PP53 Unexplained anaemia in the Elderly: High prevalence of functional iron deficiency and underdiagnosed myelodysplasia

BJH - volume 8, issue Abstract Book BHS, february 2017

L. Sattar , M. Maerevoet MD, D. Bron MD, PhD, B. Cantinieaux , P. Hermans MD, PhD, T. Pepersack MD, PhD

Read more

Highlights in aggressive lymphoma

BJH - volume 8, issue 1, february 2017

M. Maerevoet MD


ASH 2016 again featured a plethora of abstracts dedicated to lymphoma. In this summary we will discuss the studies that, in our opinion, have the highest relevance for daily clinical practice. This summary will not address indolent lymphoma as this will be covered in another article in this ASH special.

(BELG J HEMATOL 2017;8(1):10–3)

Read more

P1.12 Identification of clinical and biological parameters predictive of chemotherapy completion and two-year overall survival in clinically fit older patients with haematological malignancies

BJH - volume 7, issue Abstract Book BHS, january 2016

S. Dubruille PhD, Y. Libert PhD, M. Roos , S. Vandenbossche , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, A. Etienne , C. Reynaert , D. Razavi MD, PhD, D. Bron MD, PhD

Read more

New perspectives with PI3K inhibitors in B-cell malignant hemopathies

BJH - volume 6, issue 4, october 2015

D. Bron MD, PhD, M. Maerevoet MD


Phosphoinositide 3-kinase inhibitors represent a new group of promising targeted therapies for malignant hemopathies and primarily lymphoproliferative disorders. This short report summarises recent knowledge on the mechanism of action, the rationale to use it in humans bearing malignant hemopathies and preliminary clinical trials’ data that led to the Food and Drug Administration approval of one of these compounds (idelalisib).

(BELG J HEMATOL 2015;6(4): 152–5)

Read more

Challenges in the management of diffuse large B-cell lymphoma in older and much older patients

BJH - volume 6, issue 1, march 2015

M. Maerevoet MD, J. Vouriot MD, N. Meuleman MD, PhD, D. Bron MD, PhD


Diffuse large B-cell lymphoma is a frequent pathology in older individuals, and though curable by R-CHOP 21, treatment toxicity increases in frail patients. Therefore, therapeutic choices have to take into account Comprehensive Geriatric Assessment in addition to Performance Status, but reliable and standardised clinical decision-making tools are sorely lacking. However, Mabthera-containing treatments adapted for frail patients and co-morbidities can be used with a satisfactory survival rate at two years. Nevertheless, the main cause of death remains disease progression.

(BELG J HEMATOL 2014;6(1):4–9)

Read more

P1.14 Monoclonal B-cell lymphocytosis (MBL): results of a routine screening in a general hospital

BJH - volume 6, issue Abstract Book BHS, january 2015

G. Claes , D. Bron MD, PhD, M. Maerevoet MD, S. Benghiat MD, PhD, V. De Wilde MD, PhD, B. Bailly MD, N. Istaces , J. Brauner MD, O. Pradier MD, PhD, N. Meuleman MD, PhD

Read more

O.1 ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): final results of LYSA H34 trial

BJH - volume 5, issue Abstract Book BHS, january 2014

M. André MD, PhD, B. De Prijck MD, A. Kentos MD, PhD, A. Van Hoof MD, PhD, C. Bonnet MD, PhD, A. Sonet MD, M. Maerevoet MD, E. Van den Neste MD, PhD, A. Bosly MD, PhD, N. Mounier

Read more